Viemed Healthcare, Inc.
- Open
- 11.45
- Day high
- 11.84
- Day low
- 11.43
- Prev close
- 11.40
- Volume
- 116K
- Mkt cap
- $454M
- P/E (TTM)
- 30.6
- EPS (TTM)
- $0.39
- P/B
- 3.2
- P/S
- 1.6
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$232K over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions accumulating (13F)
Viemed Healthcare, Inc. (VMD) is a Healthcare company listed on NASDAQ. The stock is up 63% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
Viemed Healthcare, Inc. (VMD) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
VMD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.09 | $0.06 | -33.3% | $75M | +1.4% |
| Mar 5, 2026 | $0.12 | $0.14 | +16.7% | $76M | -1.5% |
| Nov 5, 2025 | $0.09 | $0.09 | +0.0% | $72M | -7.4% |
| Mar 10, 2025 | $0.11 | $0.10 | -9.1% | $61M | +2.2% |
| Mar 6, 2024 | $0.10 | $0.09 | -10.0% | $52M | +0.5% |
| Nov 1, 2023 | $0.09 | $0.07 | -22.2% | $49M | -2.1% |
| Mar 2, 2023 | $0.04 | $0.06 | +50.0% | $38M | -0.6% |
| Nov 1, 2022 | $0.05 | $0.03 | -40.0% | $36M | +2.8% |
| Aug 2, 2022 | $0.07 | $0.02 | -71.4% | $33M | +3.1% |
| May 3, 2022 | $0.05 | $0.04 | -20.0% | $32M | +5.2% |
| Mar 7, 2022 | $0.06 | $0.10 | +66.7% | $32M | +8.7% |
| May 3, 2021 | $0.06 | $0.04 | -33.3% | $28M | -25.0% |
VMD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 26, 2026 | Smokoff Timothydirector | Sell | 5,000 | $11.56 |
| Jun 26, 2026 | Frazier Williamdirector, officer: Chief Medical Officer | Sell | 10,000 | $11.72 |
| Jun 26, 2026 | Frazier Williamdirector, officer: Chief Medical Officer | Option | 10,000 | $1.81 |
| Jun 26, 2026 | Smokoff Timothydirector | Sell | 3,364 | $11.50 |
| Jun 26, 2026 | Smokoff Timothydirector | Sell | 1,636 | $11.48 |
| Mar 20, 2026 | Moore Michaelofficer: President | Sell | 40,232 | $9.21 |
| Mar 20, 2026 | Moore Michaelofficer: President | Sell | 65,000 | $8.77 |
| Mar 20, 2026 | Moore Michaelofficer: President | Sell | 31,570 | $9.42 |
| Feb 2, 2026 | Trahan Jeremyofficer: General Counsel | Option | 10,774 | — |
| Feb 2, 2026 | ZEHNDER WILLIAM TODDdirector, officer: Chief Operating Officer | Option | 8,948 | — |
| Feb 2, 2026 | ZEHNDER WILLIAM TODDdirector, officer: Chief Operating Officer | Option | 26,842 | — |
| Feb 2, 2026 | Frazier Williamdirector, officer: Chief Medical Officer | Option | 2,334 | — |
| Feb 2, 2026 | Hoyt Caseydirector, officer: Chief Executive Officer | Option | 39,795 | — |
| Feb 2, 2026 | Hoyt Caseydirector, officer: Chief Executive Officer | Tax | 13,913 | $7.48 |
| Feb 2, 2026 | ZEHNDER WILLIAM TODDdirector, officer: Chief Operating Officer | Tax | 11,368 | $7.48 |
Source: VMD SEC Form 4 filings, latest Jun 26, 2026. For informational purposes only — not investment advice.
See the full VMD insider & 13F page →Viemed Healthcare, Inc. company profile
Overview
Viemed Healthcare, Inc. (NASDAQ:VMD) is a Lafayette, Louisiana-based healthcare company founded in 2006 that provides in-home durable medical equipment and post-acute respiratory healthcare services. The company went public in August 2019 and has grown through both organic expansion and strategic acquisitions to become a significant player in the home respiratory care market. Viemed serves patients across all 50 states, focusing primarily on chronic obstructive pulmonary disease (COPD) management, sleep apnea treatment, and related respiratory therapies delivered directly to patients' homes.
Business
Viemed operates in the durable medical equipment (DME) industry, specifically focusing on respiratory healthcare services delivered in patients' homes. The company addresses a massive underserved market, with an estimated 25 million COPD patients and 80 million undiagnosed sleep apnea patients in the United States. The company operates four primary business segments: Ventilation Services (approximately 55-56% of revenue): This core segment provides non-invasive ventilation therapy primarily for COPD patients. The service includes rental of ventilators, positive airway pressure machines, and related equipment, along with ongoing clinical support and monitoring. COPD is a progressive lung disease that makes breathing difficult, and non-invasive ventilation helps patients breathe more effectively without requiring surgical intervention. Sleep Business (approximately 15-17% of revenue): This rapidly growing segment focuses on sleep apnea management, providing continuous positive airway pressure (CPAP), automatic CPAP, and bi-level positive airway pressure machines. Sleep apnea is a condition where breathing repeatedly stops and starts during sleep, and these devices help maintain open airways. The company also offers in-home sleep apnea testing services. Oxygen Business (approximately 10% of revenue): Provides oxygen concentrator units and related equipment for patients requiring supplemental oxygen therapy, typically those with severe respiratory conditions. Staffing Business (approximately 10% of revenue): Offers healthcare staffing solutions, with approximately 80% of this business driven by behavioral health needs, leveraging the company's expertise in clinical care coordination.
Revenue model
Viemed generates revenue through multiple streams within its equipment rental and healthcare services model. The primary revenue source is equipment rental fees paid by insurance providers, including Medicare, Medicaid, and private insurance plans. Patients typically receive equipment through monthly rental arrangements, creating recurring revenue streams. The company also generates income through resupply services, providing ongoing supplies and replacement parts for rented equipment. Additionally, Viemed earns revenue from direct equipment sales in certain circumstances and clinical services fees for patient monitoring and care coordination. Key factors that influence Viemed's margins include reimbursement rate changes from the Centers for Medicare & Medicaid Services (CMS), which can significantly impact profitability given the company's heavy reliance on government-funded healthcare programs. The company benefits from economies of scale as it grows its patient base, spreading fixed costs across more patients. Competition from other DME providers and potential changes in medical policies by Medicare Advantage plans can pressure margins. Conversely, the company's focus on high-acuity, complex respiratory care creates barriers to commoditization and supports premium pricing. Technology investments in patient monitoring and care coordination platforms help improve operational efficiency and clinical outcomes, potentially supporting higher reimbursement rates. The ongoing consolidation in the DME industry and Viemed's scale advantages position it favorably against smaller competitors.
Competitive moat
Viemed's competitive moat is moderate but strengthening, built primarily around operational scale, regulatory expertise, and clinical specialization. The company benefits from significant barriers to entry in the DME industry, including complex Medicare certification requirements, state licensing obligations, and the substantial capital investment needed for equipment inventory and clinical infrastructure. The company's specialized focus on complex respiratory care creates differentiation from general DME providers, as managing ventilator patients requires clinical expertise and 24/7 monitoring capabilities. Viemed's proprietary technology platforms, including the Engage Care Manager system, provide operational advantages and improve patient outcomes, potentially supporting better reimbursement rates. However, the moat faces several challenges. The company operates in a heavily regulated, reimbursement-dependent industry where government policy changes can significantly impact profitability. Large healthcare conglomerates with greater resources could potentially enter the market, and the rise of integrated health systems providing in-house DME services represents a structural threat. The relatively low switching costs for patients and referral sources, combined with the standardized nature of much DME equipment, limits pricing power. While Viemed has achieved meaningful scale with national coverage, the fragmented nature of the DME market means numerous regional competitors continue to operate successfully in local markets.
Risks & safety
Viemed demonstrates a strong margin of safety from a financial stability perspective, though valuation metrics suggest limited upside at current prices. • Liquidity and Solvency: The company maintains a robust balance sheet with $10.2 million in cash, minimal debt (debt-to-equity ratio of 0.05), and positive free cash flow generation. Current ratio of 1.38 indicates adequate short-term liquidity, though the recent negative free cash flow of -$12.6 million in Q1 2025 primarily reflects acquisition-related capital deployment. • Valuation Metrics: Current P/E ratio of 27.3x appears elevated for a mature healthcare services company, while EV/EBITDA of 17.3x suggests the market is pricing in significant growth expectations. Price-to-book ratio of 2.13x is reasonable given the company's asset-light model and growth profile. • Other Considerations: The company's dependence on government reimbursement creates regulatory risk, but its diversified payer mix and focus on medically necessary services provide some protection. Strong operational cash flow generation and disciplined capital allocation support financial stability.
Recent development
Over the past few years, Viemed has executed a comprehensive transformation from a primarily ventilator-focused company to a diversified respiratory healthcare provider. The company successfully restructured its sales organization in 2024, temporarily slowing hiring to train new managers and optimize territories, before resuming aggressive expansion in 2025. Strategic acquisitions have been central to Viemed's growth strategy. The company acquired HMP in 2023, which immediately contributed to revenue growth and expanded geographic reach. In early 2024, Viemed acquired East Alabama HomeMed, establishing a successful joint venture model. Most recently, the company signed an agreement to acquire Lehan's Medical Equipment for $26 million, expanding its presence in Northern Illinois and Chicago while adding capabilities in women's health services. Technology development has accelerated significantly, with the launch of the proprietary Engage Care Manager platform for provider communication and patient monitoring. The company is beta testing machine learning tools to optimize patient care and operational efficiency. These technology investments support Viemed's strategy of providing high-touch, high-technology care that differentiates it from commodity DME providers. Business diversification has reduced dependence on the core ventilation segment from 77% of revenue in 2021 to approximately 55% currently. The sleep business has shown particularly strong growth, increasing 46% year-over-year, while the staffing division has expanded into behavioral health services. The company has also enhanced its oxygen therapy and resupply services, creating multiple revenue streams from each patient relationship.
VMD company profile · for informational purposes only — not investment advice.
Track VMD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free